Related references
Note: Only part of the references are listed.GLP-1 Receptor Agonists and Cardiovascular Disease: a Meta-Analysis of Recent Cardiac Outcome Trials
Xiaoming Jia et al.
CARDIOVASCULAR DRUGS AND THERAPY (2018)
Patient perceptions of injection devices used with dulaglutide and liraglutide for treatment of type 2 diabetes
Louis S. Matza et al.
CURRENT MEDICAL RESEARCH AND OPINION (2018)
Effects of exenatide once weekly plus dapagliflozin, exenatide once weekly, or dapagliflozin, added to metformin monotherapy, on body weight, systolic blood pressure, and triglycerides in patients with type 2 diabetes in the DURATION-8 study
Serge A. Jabbour et al.
DIABETES OBESITY & METABOLISM (2018)
Efficacy of glucagon-like peptide-1 receptor agonists compared to dipeptidyl peptidase-4 inhibitors for the management of type 2 diabetes: A meta-analysis of randomized clinical trials
Susan Tran et al.
DIABETES OBESITY & METABOLISM (2018)
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM-2018 EXECUTIVE SUMMARY
Alan J. Garber et al.
ENDOCRINE PRACTICE (2018)
Clinical pharmacology of glucagon-like peptide-1 receptor agonists
Dimitrios Sfairopoulos et al.
HORMONES-INTERNATIONAL JOURNAL OF ENDOCRINOLOGY AND METABOLISM (2018)
Incretin-based therapy in type 2 diabetes: An evidence based systematic review and meta-analysis
Greer Waldrop et al.
JOURNAL OF DIABETES AND ITS COMPLICATIONS (2018)
Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial
Richard E. Pratley et al.
LANCET DIABETES & ENDOCRINOLOGY (2018)
Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis
M. Angelyn Bethel et al.
LANCET DIABETES & ENDOCRINOLOGY (2018)
Dulaglutide as add-on therapy to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes (AWARD-10): a 24-week, randomised, double-blind, placebo-controlled trial
Bernhard Ludvik et al.
LANCET DIABETES & ENDOCRINOLOGY (2018)
Effect of once-weekly dulaglutide on glycated haemoglobin (HbA1c) and fasting blood glucose in patient subpopulations by gender, duration of diabetes and baseline HbA1c
Baptist Gallwitz et al.
DIABETES OBESITY & METABOLISM (2018)
Effects of glucagon-like peptide-1 receptor agonists on cardiovascular risk factors: A narrative review of head-to-head comparisons
Niels B. Dalsgaard et al.
DIABETES OBESITY & METABOLISM (2018)
Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2018
DIABETES CARE (2018)
Glucagon-like peptide-1 receptor agonists compared with basal insulins for the treatment of type 2 diabetes mellitus: a systematic review and meta-analysis
Sonal Singh et al.
DIABETES OBESITY & METABOLISM (2017)
Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon-like peptide-1 receptor agonists: A systematic analysis of published clinical trials
Karolin Bettge et al.
DIABETES OBESITY & METABOLISM (2017)
Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes
Rury R. Holman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Safety and efficacy of a glucagon-like peptide-1 receptor agonist added to basal insulin therapy versus basal insulin with or without a rapid-acting insulin in patients with type 2 diabetes: results of a meta-analysis
Carol H. Wysham et al.
POSTGRADUATE MEDICINE (2017)
Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus: A Position Statement of the Korean Diabetes Association
Hyun Jin Kim et al.
DIABETES & METABOLISM JOURNAL (2017)
Glucagon-like peptide- I receptor agonists: a systematic review of comparative effectiveness research
Philip A. Levin et al.
DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY (2017)
Predictors of response to glucagon-like peptide-1 receptor agonists: a meta-analysis and systematic review of randomized controlled trials
Matteo Monami et al.
ACTA DIABETOLOGICA (2017)
Glucagon-like Peptide-1 Receptor Agonists: A Class Update for Treating Type 2 Diabetes
Julie A. Lovshin
CANADIAN JOURNAL OF DIABETES (2017)
Safety issues with glucagon-like peptide-1 receptor agonists (pancreatitis, pancreatic cancer and cholelithiasis): Data from randomized controlled trials
Matteo Monami et al.
DIABETES OBESITY & METABOLISM (2017)
Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors
Michael A. Nauck et al.
CIRCULATION (2017)
The role of glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes
Erin St Onge et al.
JOURNAL OF TRANSLATIONAL INTERNAL MEDICINE (2017)
Placebo-controlled, randomized trial of the addition of once-weekly glucagon-like peptide-1 receptor agonist dulaglutide to titrated daily insulin glargine in patients with type 2 diabetes (AWARD-9)
Paolo Pozzilli et al.
DIABETES OBESITY & METABOLISM (2017)
Pharmacologic Management of Type 2 Diabetes Mellitus: Available Therapies
James Thrasher
AMERICAN JOURNAL OF MEDICINE (2017)
Glucagon-like peptide-1 receptor agonists and risk of acute pancreatitis in patients with type 2 diabetes
Heidi Storgaard et al.
DIABETES OBESITY & METABOLISM (2017)
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM-2017 EXECUTIVE SUMMARY
Alan J. Garber et al.
ENDOCRINE PRACTICE (2017)
Review of head-to-head comparisons of glucagon-like peptide-1 receptor agonists
Sten Madsbad
DIABETES OBESITY & METABOLISM (2016)
Glucagon-like peptide-1 receptor agonists and heart failure in type 2 diabetes: systematic review and meta-analysis of randomized and observational studies
Ling Li et al.
BMC CARDIOVASCULAR DISORDERS (2016)
Physician perceptions of GLP-1 receptor agonists in the UK
Louis S. Matza et al.
CURRENT MEDICAL RESEARCH AND OPINION (2016)
Prevalence and co-prevalence of comorbidities among patients with type 2 diabetes mellitus
Kristy Iglay et al.
CURRENT MEDICAL RESEARCH AND OPINION (2016)
Evaluating the Cardiovascular Safety of New Medications for Type 2 Diabetes: Time to Reassess?
Robert J. Smith et al.
DIABETES CARE (2016)
Predictors of efficacy of GLP-1 agonists and DPP-4 inhibitors: A systematic review
Helene Bihan et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2016)
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Steven P. Marso et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Steven P. Marso et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial
Juan P. Frias et al.
LANCET DIABETES & ENDOCRINOLOGY (2016)
Once-weekly dulaglutide versus bedtime insulin glargine, both in combination with prandial insulin lispro, in patients with type 2 diabetes (AWARD-4): a randomised, open-label, phase 3, non-inferiority study
Lawrence Blonde et al.
LANCET (2015)
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
Marc A. Pfeffer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes
Silvio E. Inzucchi et al.
DIABETES CARE (2015)
Glucagon-Like Peptide-1 Receptor Agonists for Diabetes Mellitus A Role in Cardiovascular Disease
Nathaniel R. Smilowitz et al.
CIRCULATION (2014)
A comparison of adding liraglutide versus a single daily dose of insulin aspart to insulin degludec in subjects with type 2 diabetes (BEGIN: VICTOZA ADD-ON)
C. Mathieu et al.
DIABETES OBESITY & METABOLISM (2014)
Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial
Kathleen M. Dungan et al.
LANCET (2014)
Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study
John B. Buse et al.
LANCET (2013)
Adherence to Therapies in Patients with Type 2 Diabetes
Luis-Emilio Garcia-Perez et al.
DIABETES THERAPY (2013)
GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
Juris J. Meier
NATURE REVIEWS ENDOCRINOLOGY (2012)
Use of Twice-Daily Exenatide in Basal Insulin-Treated Patients With Type 2 Diabetes A Randomized, Controlled Trial
John B. Buse et al.
ANNALS OF INTERNAL MEDICINE (2011)
DURATION-5: Exenatide Once Weekly Resulted in Greater Improvements in Glycemic Control Compared with Exenatide Twice Daily in Patients with Type 2 Diabetes
Thomas Blevins et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2011)
DURATION-1 Exenatide Once Weekly Produces Sustained Glycemic Control and Weight Loss Over 52 Weeks
John B. Buse et al.
DIABETES CARE (2010)
A comparison of preferences for two GLP-1 products – liraglutide and exenatide – for the treatment of type 2 diabetes
Michael Polster et al.
JOURNAL OF MEDICAL ECONOMICS (2010)
A review of 20 years' experience with the Novopen (R) family of insulin injection devices
Jorn Rex et al.
CLINICAL DRUG INVESTIGATION (2006)
Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury
AK Bose et al.
DIABETES (2005)
Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion
LA Nikolaidis et al.
CIRCULATION (2004)
Share Paper
